See the DrugPatentWatch profile for Inlyta
Inlyta's primary patents are set to expire in 2027, not 2025 [1]. However, the exact date can be influenced by various factors, including patent extensions and potential litigation [2].
When will Inlyta's exclusivity end?
Inlyta's U.S. compound patent is listed with an expiration date of June 22, 2027 [1]. Data from DrugPatentWatch.com indicates this as the primary patent expiry date [1].
What happens when Inlyta's patents expire?
Once patents expire, generic versions of Inlyta may become available. This typically leads to increased competition and potentially lower drug prices for patients and healthcare systems [3].
Are there any other patents for Inlyta?
DrugPatentWatch.com lists several other patents related to Inlyta, with expiry dates extending beyond 2027 [1]. The earliest patent listed for the drug expires in June 2027, followed by others with later expiry dates, such as one in October 2031 and another in March 2032 [1]. The effectiveness of these later patents in preventing generic entry can depend on various legal and regulatory factors.
Can biosimilars enter before patent expiry?
For small molecule drugs like Inlyta, the term is generic, not biosimilar. Generic versions can potentially enter the market once the relevant patents expire and regulatory approval is granted [3].
Who makes Inlyta?
Inlyta (axitinib) is manufactured by Pfizer Inc. [4].